Recent JNJ News
- Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting • PR Newswire (US) • 11/19/2024 02:02:00 PM
- Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results • PR Newswire (US) • 11/18/2024 09:30:00 PM
- Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study • PR Newswire (US) • 11/14/2024 03:00:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 11/13/2024 09:45:43 PM
- Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease • PR Newswire (US) • 11/11/2024 09:05:00 PM
- Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma • PR Newswire (US) • 11/08/2024 12:00:00 PM
- Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 • PR Newswire (US) • 11/07/2024 01:00:00 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/06/2024 02:23:39 PM
- Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare • GlobeNewswire Inc. • 11/04/2024 08:11:06 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/01/2024 03:05:15 PM
- TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease • PR Newswire (US) • 10/28/2024 11:30:00 AM
- New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis • PR Newswire (US) • 10/25/2024 12:05:00 PM
- Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress • PR Newswire (US) • 10/24/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/23/2024 08:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/21/2024 10:18:23 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/18/2024 09:23:54 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/18/2024 08:47:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/15/2024 08:39:05 PM
- Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study • PR Newswire (US) • 10/15/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 11:37:20 AM
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024 • Business Wire • 10/15/2024 10:25:00 AM
- Johnson & Johnson Reports Q3 2024 Results • Business Wire • 10/15/2024 10:20:00 AM
- U.S. Index Futures Mixed; Oil Prices Fall as Israel Eases Supply Fears and China Stimulus Uncertainty Grows • IH Market News • 10/15/2024 09:49:01 AM
FEATURED Key Metals Surge, Unlocking New Opportunities for Savvy Mining Investors • Nov 19, 2024 8:45 AM
FEATURED Greenlane Signs New U.S. Distribution Agreement with Veriteque USA, Manufacturer of the SwabTek™ and Verifique™ Brand of Field Test Kits • Nov 19, 2024 8:34 AM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
Geo-Political Tensions and Trump's Increasing Military Budgets Could Boost Demand for Actelis' Cyber Hardened Networking Tech ($ASNS) • ASNS • Nov 19, 2024 10:24 AM
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary • CBDL • Nov 19, 2024 8:00 AM
North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • NBRI • Nov 18, 2024 9:00 AM